Logo

Genentech Reports New Data of Hemlibra (emicizumab-kxwh) in P-IIIb STASEY Study to Treat Hemophilia A

Share this

Genentech Reports New Data of Hemlibra (emicizumab-kxwh) in P-IIIb STASEY Study to Treat Hemophilia A

Shots:

  • The P-IIIb STASEY study evaluates the safety of Hemlibra (qw for ~2 yrs.) in 193 patients with hemophilia A with factor VIII inhibitors. The results of the study are consistent with a P- III HAVEN program
  • The results from the final analysis of a P-IIIb STASEY study showed no new thrombotic microangiopathy or thrombotic SAEs & no new safety signals were observed. The therapy showed effective bleed control with 82.6% of patients achieving zero treated bleeds
  • Additionally- the study reinforced that Hemlibra is associated with a low incidence of ADA development. The therapy is approved to treat patients with hemophilia A with/out factor VIII inhibitor in 100+/80+ countries respectively

  Ref: Business Wire | Image: Center for Health Journalism

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions